

Tolérance centrale Sélection positive et négative des répertoires lymphocytaires

Adrien Six (adrien.six@upmc.fr)
Université Pierre et Marie Curie

IF-IIIa
février 2011

IF2011 MV423 IF-IIIa

1


Sélection positive et négative des répertoires lymphocytaires

1. Introduction
2. Sélection des répertoires B
3. Sélection des répertoires T
4. Conclusion

IF2011 MV423 IF-IIIa

2

Les lymphocytes B et T




→ caractérisés par leur récepteur spécifique d'antigène

IF2011 MV423 IF-IIIa

3

Diversité des chaînes Ig et TCR

- La diversité des chaînes d'Ig et de TCR est le produit de :
 - Combinatoire des segments V(D)J
 - Appariement IgH/L, TCR α / β or TCR γ / δ
 - Ajout/élimination aléatoire de nucléotides à la jonction des segments géniques (CDR3)



IF2011 MV423 IF-IIIa

4

Estimation de la diversité (2)

TABLE 9-3 Sources of possible diversity in mouse immunoglobulin and TCR genes


Mechanism of diversity	IMMUNOGLOBULINS		$\alpha\beta$ T-CELL RECEPTOR		$\gamma\delta$ T-CELL RECEPTOR	
	H Chain	κ Chain	α Chain	β Chain	γ Chain	δ Chain
ESTIMATED NUMBER OF FUNCTIONAL GENE SEGMENTS*						
V	101	85	79	21	7	6
D	13	0	0	2	0	2
J	4	4	38	11	3	2
POSSIBLE NUMBER OF COMBINATIONS†						
Combinatorial V-J	$101 \times 13 \times 4$	85×4	79×38	$21 \times 2 \times 11$	7×3	$6 \times 2 \times 2$
and V-D-J joining	5.3×10^3	3.4×10^2	3.0×10^3	4.6×10^2	21	24
Alternative joining of D gene segments	-	-	-	(some)	-	(often)
Junctional flexibility	+	+	+	+	+	+
N-region nucleotide addition‡	+	$\sim 10^{12}$	+	$\sim 10^{15}$	+	$\sim 10^{18}$
P-region nucleotide addition	+	+	+	+	+	+
Somatic mutation	+	+	-	-	-	-
Combinatorial association of chains	+	+	+	+	+	+

*Immunoglobulin data from Table 5-2; TCR data from Baum et al., 2004, *Nucleic Acids Research* 32:D51.
†A plus sign (+) indicates mechanism makes a significant contribution to diversity but to an unknown extent.
‡A minus sign (-) indicates mechanism does not operate.
§See Figure 9-4d for theoretical number of combinations generated by N-region addition.

Table 9-3
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W. H. Freeman and Company

5


Parallèle différenciations B et T



IF2011 MV423 IF-IIIa

D'après Fitzsimmons et Hagman (1996) *Curr. Op. Immunol.* 8:166. 6

Mise en place des répertoires



IF2011 MV423 IF-IIIa

7


Sélection positive et négative des répertoires lymphocytaires

1. Introduction
2. **Sélection des répertoires B**
3. Sélection des répertoires T
4. Conclusion

IF2011 MV423 IF-IIIa


8

Sélection des lymphocytes B (1)




IF2011 MV423 IF-IIIa

Sélection des lymphocytes B (2)




IF2011 MV423 IF-IIIa

Délétion clonale (1)



IF2011 MV423 IF-IIIa

Délétion clonale (2)



IF2011 MV423 IF-IIIa

Anergie (1)




Figure 11-14a
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W.H. Freeman and Company

IF2011 MV423 IF-IIIa

13

Anergie (2)





Figure 11-14b
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W.H. Freeman and Company

IF2011 MV423 IF-IIIa

14

Sélection des lymphocytes B (3)



IF2011 MV423 IF-IIIa

15

Édition du BCR (1)




Figure 11-6a
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W.H. Freeman and Company

IF2011 MV423 IF-IIIa

16

Édition du BCR (2)


H-2^d transgenics

Figure 11-6b
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W. H. Freeman and Company

IF2011 MV423 IF-IIIa

17

Édition du BCR (3)

TABLE 11-1 Expression of transgene encoding IgM antibody to H-2 ^k class I MHC molecules			
Experimental animal	Number of animals tested	EXPRESSION OF TRANSGENE	
		As membrane Ab	As secreted Ab (µg/ml)
Nontransgenics	13	(-)	<0.3
H-2 ^d transgenics	7	(+)	93.0
H-2 ^k transgenics	6	(-)	<0.3

Table 11-1
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W. H. Freeman and Company

IF2011 MV423 IF-IIIa

18

Édition du BCR (4)


H-2^{d/k} transgenics

Figure 11-6c
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W. H. Freeman and Company

IF2011 MV423 IF-IIIa

19

Sélection des lymphocytes B (4)




Attribute	Conventional B cells (B-2 B cells)	B-1 B cells
Major sites	Secondary lymphoid organs	Peritoneal and pleural cavities
Source of new B cells	From precursors in bone marrow	Self-renewing (division of existing B-1 cells)
V-region diversity	Highly diverse	Restricted diversity
Somatic hypermutation	Yes	No
Requirements for T-cell help	Yes	No
Isotypes produced	High levels of IgG	High levels of IgM
Response to carbohydrate antigens	Possibly	Definitely
Response to protein antigens	Definitely	Possibly
Memory	Yes	Very little or none
Surface IgD on mature B cells	Present on naive B cells	Little or none

Figure 11-5
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W. H. Freeman and Company

IF2011 MV423 IF-IIIa

21

Sélection des lymphocytes B (5)



IF2011 MV423 IF-IIIa

22


Hypermutations en absence d'antigène

Table IV. Somatic mutations in JH-LJ4 junctions flanking VDJ4 rearrangements from splenic and blood B cell subsets

Donors	Age (months)	Tissue	CD30-positive B cell subsets	Number of sequences	Number of mutated sequences	Range	Number of mutations	Frequency of total sequences	Frequency of mutated sequences
D1	10	blood	IgD ⁺ CD27 ⁺	20	15	0-17	79	1.16	1.34
				18	18	0-22	117	1.20	1.80
				16	16	0-21	116	1.89	2.27
D2	10	blood	IgD ⁺ CD27 ⁺	18	15	0-21	116	1.89	2.27
				16	16	0-21	116	1.89	2.27
				16	16	0-21	116	1.89	2.27

IgM⁺IgD⁺CD27⁺ humaines


- Zone marginale de la rate
- Mutations somatiques
- Diversité CDR3 « normale »



IF2011 MV423 IF-IIIa

Weller et al. (2008) J. Exp. Med 205:1331. 29

Hypermutations en absence d'antigène



IF2011 MV423 IF-IIIa

30

Dominance clonale: idiotype T15 (1)

Anticorps inhibiteurs	Nombre de PFC anti-PC/rate
-	120 000
S1 60	115 000
S1 04	117 000
2E8	800
F6	950

-S160, S104, 2E8 et F6 sont quatre anticorps monoclonaux anti-T15, une immunoglobuline IgA_κ anti-phosphorylcholine.

-S160 est dirigé contre un épitope de Igα; S104 est spécifique de IgA_κ; 2E8 et F6 sont des anticorps anti-idiotypiques.

-Les quatre anticorps ont été utilisés pour tenter d'inhiber des plages d'hémolyses locales (PFC) obtenues en mélangeant *in vitro* des cellules de souris BALB/c anti-PC, de la PC couplée à des globules rouges de mouton et du complément.

IF2011 MV423 IF-IIIa

32

Dominance clonale: idiotype T15 (2)

TABLE 1
Number of PC-Specific Foci and Percentages of T15⁺ Foci as a Function of Development

Age of donor mice in days ^a	Number of donor mice ^b	Total number of cells analyzed	Number of PC ⁺ foci	Frequency (in 10 ⁶ spleen cells) ^c	Number of T15 ⁺ foci	%T15 ⁺
2	58	2 × 10 ⁶	0	0	0	0
3	52	2 × 10 ⁶	0	0	0	0
4	31	2 × 10 ⁶	1	0.125	0	0
6	17	2 × 10 ⁶	7	0.875	2	28.5
7	13	3 × 10 ⁶	15	1.2	6	40.0
8	7	10 ⁶	7	1.7	4	57.1
9	5	10 ⁶	13	3.2	9	69.2
10	6	1.8 × 10 ⁶	30	4.1	24	80.0
12	4	1.5 × 10 ⁶	28	4.6	25	89.2
21	1	1.2 × 10 ⁶	18	3.7	16	88.8
42-46	1	2 × 10 ⁶	69	8.6	63	91.3

^aThe day of birth was counted as day 1. Thus, an age of 2 indicates 1 day after birth, age of 3 indicates 2 days after birth, etc.

^bSpleen cells from mice born within 12 hr of each other were pooled. Results from experiments performed on different days were pooled for the table.

^cCalculated as per Sigal et al. (1977).

Vakil, Briles & Kearney (1991) *Dev. Immunol* 1:203.

IF2011 MV423 IF-IIIa

33

Dominance clonale: idiotype T15 (3)

Injection néonatale de R36A *S. pneumoniae* + challenge R36A à 7 semaines
→ Dosage Ac anti-PC




TABLE 3

Treatment of serum donor		Alive/dead postchallenge	
neonatal	adult	3 days	10 days
None	R36A	7/0	5/2
R36A	R36A	0/4 ^a	0/4 ^a
None	None	0/7 ^b	0/7 ^b
	No serum	0/7 ^b	0/7 ^b

^aDifferent from none/R36A at $p < 0.01$.

^bDifferent from none/R36A at $p < 0.001$.

^cDifferent from none/R36A at $p < 0.06$.

Challenge léthal *S. pneumoniae*
→ Pouvoir protecteur du sérum de souris préalablement exposées?

Vakil, Briles & Kearney (1991) *Dev. Immunol* 1:203.

IF2011 MV423 IF-IIIa


34

Sélection positive et négative des répertoires lymphocytaires

1. Introduction
2. Sélection des répertoires B
3. Sélection des répertoires T
4. Conclusion

IF2011 MV423 IF-IIIa

35



IF2011 MV423 IF-IIIa

Godfrey and Zlotnik (1993) *Immunol. Today* 14:457. 56


Sélections positive et négative (1)

- Sélection positive: le TCR doit avoir une certaine réactivité avec une molécule du CMH du soi
- L'expression du co-récepteur CD4/CD8 suit la restriction pour le CMH
→ CD4/classe II et CD8/classe I
- Sélection négative: les cellules T autoréactives (reconnaissant CMH + peptide du soi) sont éliminées

IF2011 MV423 IF-IIIa


57

Sélections positive et négative (2)



IF2011 MV423 IF-IIIa


58



IF2011 MV423 IF-IIIa

Godfrey and Zlotnik (1993) Immunol.Today 14:457. 59

Rôle de l'épithélium thymique dans la sélection positive (1)



IF2011 MV423 IF-IIIa

60

Rôle de l'épithélium thymique dans la sélection positive (2)


Thymectomize <i>b x k</i> mice	Graft with thymus of haplotype	Irradiate and reconstitute with <i>b x k</i> bone marrow	Prime with KLH	Proliferative response of primed T-cells to KLH on antigen-presenting cells of haplotype	
				<i>H-2^b</i>	<i>H-2^k</i>
	<i>b x k</i>	→	→	++	++
	<i>b</i>	→	→	++	-
	dGuo- treated <i>b</i>	→	→	++	-
	<i>k</i>	→	→	-	++
	dGuo- treated <i>k</i>	→	→	-	++

From: Roitt's Essential Immunology Eleventh Edition

IF2011 MV423 IF-IIIa

61


Sélection positive & CMH (1)



IF2011 MV423 IF-IIIa

64

Sélection positive & CMH (2)

Fonds C57BL/6 I-E(I-E α), I-A⁺
IF2011 MV423 IF-IIIa

Brockner, Riedinger & Karjalainen (1997) J. Exp. Med. 185:541. 65

Sélection positive & CMH (3)

TABLE 10-1 Effect of class I or II MHC deficiency on thymocyte populations*			
Cell type	Control mice	KNOCKOUT MICE	
		Class I deficient	Class II deficient
CD4 ⁻ CD8 ⁻	+	+	+
CD4 ⁺ CD8 ⁺	+	+	+
CD4 ⁺	+	+	-
CD8 ⁺	+	-	+

Table 10-1
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W. H. Freeman and Company

IF2011 MV423 IF-IIIa

66

Sélection positive & CMH (4)





Figure 10-7
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W.H. Freeman and Company

IF2011 MV423 IF-IIIa


67

Sélection positive & CMH (5)



IF2011 MV423 IF-IIIa


68



IF2011 MV423 IF-IIIa

Godfrey and Zlotnik (1993) Immunol.Today 14:457. 70

Induction de la tolérance



From: Roitt's Essential Immunology Eleventh Edition

→ Rôle des peptides du soi → Délétion clonale

IF2011 MV423 IF-IIIa

71



IF2011 MV423 IF-IIIa

72

Délétion clonale et superantigènes (1)





Figure 10-16
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W. H. Freeman and Company

IF2011 MV423 IF-IIIa

73

Délétion clonale et superantigènes (4)



IF2011 MV423 IF-IIIa

74

Délétion clonale et superantigènes (2)

TABLE 10-3 Exogenous superantigens and their V _β specificity			
Superantigen	Disease ^a	V _β SPECIFICITY	
		Mouse	Human
Staphylococcal enterotoxins			
SEA	Food poisoning	1, 3, 10, 11, 12, 17	nd
SEB	Food poisoning	3, 8.1, 8.2, 8.3	3, 12, 14, 15, 17, 20
SEC1	Food poisoning	7, 8.2, 8.3, 11	12
SEC2	Food poisoning	8.2, 10	12, 13, 14, 15, 17, 20
SEC3	Food poisoning	7, 8.2	5, 12
SED	Food poisoning	3, 7, 8.3, 11, 17	5, 12
SEE	Food poisoning	11, 15, 17	5.1, 6.1–6.3, 8, 18
Toxic shock syndrome toxin (TSST1)	Toxic shock syndrome	15, 16	2
Exfoliative dermatitis toxin (ExFT)	Scalded skin syndrome	10, 11, 15	2
Mycoplasma arthritidis supernatant (MAS)	Arthritis, shock	6, 8.1–8.3	nd
Streptococcal pyrogenic exotoxins (SPE-A, B, C, D)	Rheumatic fever, shock	nd	nd

^aDisease results from infection by bacteria that produce the indicated superantigens.

^aDisease results from infection by bacteria that produce the indicated superantigens.

Table 10-3
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W. H. Freeman and Company

IF2011 MV423 IF-IIIa

75

Délétion clonale et superantigènes (3)

TABLE II
Vβ Specificity of MMTV Encoded Super-antigens


Mtv	Chromosome	Super-antigen	Vβ specificity	References
1	7	Mls-2	3	41
2	18		14	44
3	11		3, 17a	89, 92
6	16	Etc-2/Mls-3	3, 5.1, 5.2	35, 40, 41
7	1	Mls-1	6, 7, 8.1, 9	41
8	6	Dvb11-1	5.1, 5.2, 11, 17a	39, 40
9	12	Etc-1/Dvb11-2	5.1, 5.2, 11, 12, 17a	33, 34, 38, 39, 40, 55
11	14	Dvb11-3	11	39
13	4	Mls-2	3	41
?	?		16*	26, 27
?	?		19a*	—†
?	?		20	29
C3H-exo			14, 15	42, 43
BALB/c tumor			2	90

*Super-antigen implicated but not yet demonstrated.
†R. J. Hodes, unpublished.

IF2011 MV423 IF-IIIa

Woodland & Blackman (1992) *Int. Rev. Immunol.* 8:311. 76

Délétion clonale et superantigènes (5)



© Current Biology Ltd/Garland Publishing

IF2011 MV423 IF-IIIa

© Current Biology Ltd/Garland Publishing

77

Délétion clonale et superantigènes (6)


Table 1. Strain distribution of some MTV proviruses, (adapted from *Annu. Rev. Cell Biol.* 1993 9:101-28)

MTV	1	3	6	7	8	9	11	13	14	17	23	29	30	31
Chromosome	7	11	16	1	6	12	14	4	4	4	6	6	12	Y
cM from centromere	31	72	31	73	31	40	8	47	10	20	32	20-30	2	
Vb Specificity	3, 3.5, 3.7	3, 3.5, 3.7	3, 3.5, 3.7	3, 3.5, 3.7	3, 3.5, 3.7	3, 3.5, 3.7	3, 3.5, 3.7	3, 3.5, 3.7	3, 3.5, 3.7	3, 3.5, 3.7	3, 3.5, 3.7	3, 3.5, 3.7	3, 3.5, 3.7	?
(Vb allele if not listed)	177	17	5	8.1, 11.12	11.12	11.12	12	177						
Strains	H2	IE		177	9	177	17							
A/J	a	k	-	+	-	+	-	+	-	+	-	-	-	-
AKR/J	k	k	-	-	+	+	+	-	-	+	+	-	+	+
BALB/cByJ	d	d	-	+	-	+	+	-	-	-	-	-	-	-
B10.BR	k	k	-	-	-	+	+	-	-	+	-	-	+	-
C3H/HeJ	k	k	+	+	-	+	+	+	+	-	-	-	-	-
C57BL/6J	b	-	-	-	-	+	+	-	-	+	-	-	+	-
C57BR/cdJ(a)	k	k	-	-	-	+	+	+	-	+	-	+	+	?
C57L/J (a)	b	-	-	-	-	+	+	+	-	+	-	+	-	?
C58/J	k	k	-	+	-	+	-	-	-	+	-	-	+	-
CBA/CaJ	k	k	-	-	-	+	+	-	-	+	-	-	-	-
CBA/J	k	k	-	+	+	+	+	-	-	+	-	-	-	-

IF2011 MV423 IF-IIIa

Scherer et al. (1993) *Annu. Rev. Cell Biol.* 9:101. 78


Sélection négative & superantigène (7)




IF2011 MV423 IF-IIIa

Baey & Thomas-Vaslin (2009) non publié. 79

Sélection négative & superantigène (8)

Fonds C57BL/6 I-E α^d (I-E α^d), I-A $^+$
IF2011 MV423 IF-IIIaBrockner, Riedinger & Karjalainen (1997) *J. Exp. Med.* 185:541. 80


Délétion clonale et TCR transgénique



IF2011 MV423 IF-IIIa

81

Sélection et TCR transgénique


Figure 10-8
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W. H. Freeman and Company

IF2011 MV423 IF-IIIa

83

Culture organotypique de thymus foetal

Experimental procedure—fetal thymic organ culture (FTOC)

Figure 10-9a
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W. H. Freeman and Company

IF2011 MV423 IF-IIIa

85

Rôle du peptide dans la sélection

Development of CD8⁺ CD4⁻ MHC I-restricted cells





Figure 10-9b
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W. H. Freeman and Company

IF2011 MV423 IF-IIIa

86

Rôle du peptide dans la sélection



IF2011 MV423 IF-IIIa

87

Peptides agonistes, antagonistes (1)

Peptide ligand altéré (APL)
= peptide analogue d'un peptide immunogène

Agoniste → Conserve certaines fonctions d'activation


Antagoniste passif → Compétition pour le CMH

Antagoniste actif → induction d'anergie, modification de la cascade d'activation

IF2011 MV423 IF-IIIa

88


Peptides agonistes, antagonistes (2)



IF2011 MV423 IF-IIIa

D'après Sloan-Lancaster et Allen (1996) *Annu. Rev. Immunol.* 14:1-23

Peptides agonistes, antagonistes (3)



IF2011 MV423 IF-IIIa

90

Expression des peptides du soi dans le thymus sous contrôle de AIRE

- AIRE fait partie d'un complexe multiprotéique
- Activateur transcriptionnel ectopique
- Expression dans le thymus, en particulier au niveau des cellules épithéliales médullaires (mTEC)

Table 1. Summary of the cell type-specific pattern of promiscuous gene expression

	SAP	CDP	Complement C5	α-fetoprotein	Albumin	Haptoglobin	α1-antitrypsin	PLP	MDG	STDP	GAD67	GAD65	Somatostatin	Tyrosinase	Insulin	Glucose	PIA	Thyroglobulin	Lactalbumin	Retinal S antigen	NACR1	IFABP	Amylase1
cTECs	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
mTECs	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
DCs	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Macrophages	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

Derbinski et al. (2001) Nat. Immunol. 2:1032.

- Déficience de AIRE (souris knock-out; syndrome APECED chez l'homme) → autoimmunité +++

IF2011 MV423 IF-IIIa

92


AIRE prévient l'autoimmunité

- Génération de souris knock-out pour AIRE:
 - augmentation avec l'âge de la fréquence de pathologies autoimmunes spécifiques d'organes
 - infiltrat lymphocytaire dans de nombreux organes
 - production d'autoanticorps spécifiques d'organes

Infiltrats lymphocytaires:


Sex	Age	Salivary	Respiratory	Thyroid	Retina	Liver	Stomach
F	3	-	-	-	ND	-	-
M	4	-	-	-	ND	-	-
M	4	-	-	-	ND	-	-
F	9	+	-	-	ND	-	-
F	9	+	-	-	ND	-	-
M	9	+	-	-	ND	-	-
M	10	+	-	-	ND	-	-
M	15	+	-	-	ND	-	-
F	15	+	+	+	+	+	+
F	15	+	+	+	+	+	+
F	22	+	+	+	+	+	+
M	30	+	+	+	+	+	+
F	31	+	+	+	+	+	+
M	35	+	+	+	+	+	+

Derbinski et al. (2001) Nat. Immunol. 2:1032.



IF2011 MV423 IF-IIIa

93




IF2011 MV423 IF-IIIa

Godfrey and Zlotnik (1993) Immunol. Today 14:457.

94

Sélection CD8/CMHI & CD4/CMHII (1)



IF2011 MV423 IF-IIIa

95

Sélection CD8/CMHI & CD4/CMHII (2)

INSTRUCTIVE MODEL




Figure 10-10 part 1
 Kuby IMMUNOLOGY, Sixth Edition
 © 2007 W. H. Freeman and Company

IF2011 MV423 IF-IIIa

97

Sélection CD8/CMHI & CD4/CMHII (3)

STOCHASTIC MODEL





Figure 10-10 part 2
 Kuby IMMUNOLOGY, Sixth Edition
 © 2007 W. H. Freeman and Company

IF2011 MV423 IF-IIIa

98

Sélection CD8/CMHI & CD4/CMHII (4)

Modèle cinétique d'engagement CD4/CD8




Current Opinion in Immunology

IF2011 MV423 IF-IIIa

Singer, A. (2002) Curr.Opin.Immunol. 14, 207-215

Sélection CD8/CMHI & CD4/CMHII (5)

Modèle cinétique d'engagement CD4/CD8




IF2011 MV423 IF-IIIa

Singer, A. (2002) *Curr.Opin.Immunol.* 14, 207-215

Sélection CD8/CMHI & CD4/CMHII (6)


Modèle cinétique d'engagement CD4/CD8



IF2011 MV423 IF-IIIa

Singer, A. (2002) *Curr.Opin.Immunol.* 14, 207-215

Sélection CD8/CMHI & CD4/CMHII (7)



Fonds C57BL/6 H-2^b
 LLO₁₉₀₋₂₀₁ → I-A^b
 OVA₂₅₇₋₂₆₄ → K^b

IF2011 MV423 IF-IIIa


Tyznik, Sun & Bevan (2004) *J. Exp. Med.* 199:559. 103

Conclusion

IF2011 MV423 IF-IIIa

104

Sélections centrale et périphérique



IF2011 MV423 IF-IIIa

105

Notions de répertoires (3)

- La diversité des récepteurs spécifiques de l'antigène du répertoire disponible de lymphocytes matures périphériques conditionne la capacité à répondre aux **antigènes du non-soi**.
- Cette diversité disponible est en fait façonnée, notamment pendant la différenciation lymphocytaire, par les **antigènes du soi**.

IF2011 MV423 IF-IIIa

106

There is only one immune system! The view from immunopathology. A. M. Silverstein and N. R. Rose. *Semin. Immunol.* 12:173-178, 2000.

- The immune system does not 'decide' that a stimulus is deadly or harmless and respond accordingly.
- The world is not divided between the self and the not-self (foreign). The immune system does not 'know' the difference. Only obedience to the immunological rules defines what is tolerated and what is intolerable.
- SELF IS ONLY THAT COLLECTION OF POTENTIAL IMMUNOGENS THAT CANNOT STIMULATE A RESPONSE (or only a subliminal one) AT THAT TIME AND PLACE! This inability, which we name immunological tolerance [...] is the result of a multitude of central and peripheral down-regulatory mechanisms that have acted according to their own rules.
- Any 'foreign' epitope can become 'self' if administered appropriately, and any 'self' epitope can become 'foreign' and cause autoimmune disease, if tolerance is overcome with an adjuvant, by an intercurrent infection, by molecular mimicry, or by a variety of other means.
- Again, the immune system does not 'choose' immunoprotection or immunopathology in response to a challenge; both will occur in any event, and the fixed rules only determine the relative balance of the two.

IF2011 MV423 IF-IIIa

107